

Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies

Miguel Méndez,¹ Marina Magrey,² Marleen Van de Sande,^{3,4} Maxime Breban,⁵ Filip Van den Bosch,⁶ Carmen Fleurinck,⁷ Ute Massow,⁸ Natasha de Peyrecave,⁷ Thomas Vaux,⁹ Xenofon Baraliakos,¹⁰ Helena Marzo-Ortega¹¹

Objective

To report the efficacy of bimekizumab over multiple efficacy endpoints to Week 52 in tumour necrosis factor inhibitor-naïve or -inadequate responder patients across the full disease spectrum of axial spondyloarthritis, pooled across two phase 3 studies.

Background

- In patients with non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic (r-) axSpA (i.e., ankylosing spondyloarthritis),¹ tumour necrosis factor inhibitors (TNFi) are commonly used as a first line biologic treatment.
- However, many patients experience loss of response over time, and some patients have intolerance or contraindication to TNFi.² Efficacy of second line biologics is typically limited in TNFi-inadequate responders (IRs) compared with TNFi-naïve patients.³
- Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.
- In the phase 3 BE MOBILE 1 and 2 studies, BKZ demonstrated efficacy across the disease spectrum of axSpA and ASAS40 responses at Week 52 were similar in TNFi-naïve and TNFi-IR patients receiving BKZ.⁴

Materials and Methods

- The parallel BE MOBILE 1 (nr-axSpA; NCT03928704) and 2 (r-axSpA; NCT03928743) studies each comprised a 16-week double-blind, placebo-controlled period followed by a 36-week maintenance period (Figure 1).⁴
- This post hoc analysis reports pooled efficacy data, through Week 52, stratified by prior TNFi exposure (naïve or IR, i.e., those who have experienced loss of efficacy, contraindication or intolerance to TNFi treatment). Only one prior TNFi use was permitted per patient.
 - From Week 16, data reported only for patients continuously treated with BKZ.
- Data are reported with non-responder imputation, observed case methodology or multiple imputation.
- Treatment-emergent adverse events (TEAEs; MedDRA v19.0) in BKZ-randomised TNFi-naïve and TNFi-IR patients are reported to Week 52 for patients who had received at least one dose of BKZ.

Results

Patients

- This pooled analysis included 505 TNFi-naïve (nr-axSpA: 227; r-axSpA: 278) and 81 TNFi-IR (nr-axSpA: 27; r-axSpA: 54) patients.
 - 302 (59.8%) TNFi-naïve and 47 (58.0%) TNFi-IR patients were randomised to BKZ.
- Baseline characteristics are shown in Table 1.

Efficacy

- At Week 16, the proportion of patients achieving ASAS40 and ASDAS low disease activity (<2.1) was higher in BKZ-randomised vs placebo-randomised patients, regardless of prior TNFi exposure (Figures 2–3).
 - Responses in continuous BKZ-treated patients increased to Week 52.
- Substantial reductions from baseline in BASDAI and MRI inflammation in the sacroiliac joints and spine were also achieved with BKZ vs placebo in both TNFi-naïve and TNFi-IR patients at Week 16; in continuous BKZ-treated patients, this was sustained or further improved at Week 52 (Table 2).
- Comparable improvements in physical functioning (BASFI), nocturnal spinal pain and health-related quality of life (ASQoL) were observed through 52 weeks with BKZ in TNFi-naïve and TNFi-IR patients (Table 2).

Safety

- From baseline to Week 52, exposure-adjusted incidence rates (EAIRs) per 100 patient years (PY) for any TEAEs were 197.8 and 233.6 for BKZ-randomised TNFi-naïve and TNFi-IR patients, respectively. No deaths occurred (Table 3).
- Most frequently reported TEAEs were nasopharyngitis, upper respiratory tract infection and oral candidiasis for both subgroups.

Conclusions

Across the full disease spectrum of axSpA, bimekizumab treatment resulted in clinically relevant improvements in signs and symptoms, disease activity, suppression of inflammation, physical functioning and health-related quality of life. These improvements were seen regardless of prior TNFi exposure and sustained to Week 52. Similar results have been demonstrated in phase 3 studies of bimekizumab in psoriatic arthritis.⁵

Summary

In patients with axSpA, bimekizumab treatment resulted in clinically relevant improvements, regardless of prior TNFi-exposure, in:






Figure 2 Achievement of ASAS40 over 52 weeks in pooled A) TNFi-naïve and B) TNFi-IR patients from BE MOBILE 1 and 2 (NRI)



Data are pooled from BE MOBILE 1 and 2. Missing data were imputed with NRI. Data from PBO-randomised patients not included from Week 16 onwards.

Figure 3 Achievement of ASDAS <2.1 (low disease activity) over 52 weeks in pooled A) TNFi-naïve and B) TNFi-IR patients from BE MOBILE 1 and 2 (OC)



Data are pooled from BE MOBILE 1 and 2 and reported using OC. *In Figure 3B, 7 continuously BKZ-treated patients were identified as being responders at Week 12 and non-responders at Week 16; all were male and the 6 were patients with r-axSpA. Of these 7 patients, the 6 patients with r-axSpA all became responders again at Week 24. All ASDAS differences in these patients between Week 12 and Week 16 were less than 1. Data from PBO-randomised patients not included from Week 16 onwards.

ASAS40: Assessment of SpondyloArthritis International Society 40 response; **ASDAS:** Ankylosing Spondylitis Disease Activity Score; **ASQoL:** Ankylosing Spondylitis Quality of Life; **axSpA:** axial spondyloarthritis; **BASDAI:** Bath Ankylosing Spondylitis Disease Activity Index; **BASFI:** Bath Ankylosing Spondylitis Functional Index; **BKZ:** bimekizumab; **CFB:** change from baseline; **CRP:** C-reactive protein; **csDMARD:** conventional synthetic disease-modifying antirheumatic drug; **EAIR:** exposure-adjusted incidence rate; **HLA-B27:** human leukocyte antigen B27; **HRQoL:** health-related quality of life; **hs-CRP:** high sensitivity CRP; **IBD:** inflammatory bowel disease; **IR:** inadequate responder; **LDA:** low disease activity; **MI:** multiple imputation; **MRI:** magnetic resonance imaging; **n:** number; **nr-axSpA:** non-radiographic axSpA; **NRI:** non-responder imputation; **NSAID:** non-steroidal anti-inflammatory drug; **OC:** observed case; **PBO:** placebo; **PY:** patient years; **Q4W:** every four weeks; **r-axSpA:** radiographic axSpA; **SD:** standard deviation; **SE:** standard error; **SJ:** sacroiliac joints; **SPARCC:** Spondyloarthritis Research Consortium of Canada; **TEAE:** treatment-emergent adverse event; **TNFi:** tumour necrosis factor inhibitor; **ULN:** upper limit of normal.

Affiliations: ¹UCB Pharma, Madrid, Spain; ²Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA; ³Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands; ⁴Amsterdam Rheumatology & Immunology Center (ARIC), Academic Medical Center, Amsterdam, The Netherlands; ⁵CHU Ambriose-Paré, Boulogne-Billancourt, Paris, France; ⁶Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium; ⁷UCB Pharma, Brussels, Belgium; ⁸UCB Pharma, Monheim am Rhein, Germany; ⁹UCB Pharma, Slough, UK; ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany; ¹¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

References: ¹Boel A. Ann Rheum Dis 2019;78(11):1545–9; ²Nouredin B. Rheumatol (Oxf) 2018;57(suppl 6); ³Navarro-Compán V. RMD Open 2017;3:e00524; ⁴Van der Heijde D. Ann Rheum Dis 2023;01:1–12; ⁵Mease P. Arthritis Rheumatol 2022;74(suppl 9). **Author Contributions:** Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **MMe, MM, MvdS, MB, FvdB, CF, UM, NdP, TV, XB, HMO.** Drafting of the publication, or revising it critically for important intellectual content: **MMe, MM, MvdS, MB, FvdB, CF, UM, NdP, TV, XB, HMO.** Final approval of the publication: **MM, MvdS, MB, FvdB, CF, UM, NdP, TV, XB, HMO.** Consultancy fees from AbbVie, Bristol-Myers Squibb and UCB Pharma; grant/research from AbbVie, Bristol-Myers Squibb and UCB Pharma; speakers bureau from AbbVie, Bristol-Myers Squibb and UCB Pharma; grant/research from MSD; **FvdB:** Consultancy fees from AbbVie, Amgen, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma; speakers bureau from AbbVie, Amgen, Janssen, Merck, Novartis, Pfizer and UCB Pharma; **CF:** Employee and shareholder of UCB Pharma; **UM, NdP, TV:** Employees of UCB Pharma; **XB:** Speakers bureau from AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB Pharma; consultant of AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB Pharma; grant/research support from: Novartis and UCB Pharma; **HMO:** Speaking honoraria and/or consultancy fees from AbbVie, Amgen, Biogen, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, Takeda, and UCB Pharma; research grants from: Janssen, Novartis, Pfizer, and UCB Pharma. **Acknowledgements:** We would like to thank the patients and their caregivers in addition to all the investigators and their teams who contributed to this study. The authors acknowledge Celia Menclenberg, PhD, UCB Pharma, for publication coordination, Elise Fung, BSc, Costello Medical, London, UK for medical writing, Shmala Siddiqui, MSc, MBA, Costello Medical, Manchester, UK for editorial assistance, and the Costello Medical Creative team for study support. These studies were funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.

Figure 1 BE MOBILE 1 and 2 study designs




Table 1 Pooled baseline characteristics across BE MOBILE 1 and 2 in TNFi-naïve and TNFi-IR patients

Mean (SD), unless otherwise specified	TNFi-naïve		TNFi-IR	
	PBO n=203	BKZ 160 mg Q4W n=302	PBO n=34	BKZ 160 mg Q4W n=47
Age, years	38.4 (12.2)	40.4 (11.7)	44.7 (10.5)	40.7 (12.8)
Male, n (%)	126 (62.1)	200 (66.2)	19 (55.9)	33 (70.2)
HLA-B27 positive, n (%)	159 (78.3)	252 (83.4)	28 (82.4)	42 (89.4)
r-axSpA, n (%)	94 (46.3)	184 (60.9)	17 (50.0)	37 (78.7)
Disease duration ≥2 years, n (%)	86 (42.4)	141 (46.7)	31 (91.2)	42 (89.4)
ASDAS	3.7 (0.7)	3.7 (0.8) ^a	3.8 (0.7)	3.9 (0.8)
BASDAI	6.5 (1.3)	6.6 (1.3)	6.9 (1.3)	6.6 (1.3)
hs-CRP, mg/L, geometric mean (geometric CV, %)	5.8 (212.3)	5.4 (285.2)	5.4 (250.8)	8.8 (269.5)
hs-CRP >ULN ^a , n (%)	120 (59.1)	174 (57.6)	18 (52.9)	33 (70.2)
Total spinal pain	7.1 (1.4)	7.2 (1.6)	7.5 (1.4)	7.1 (1.4)
ASQoL, mean (SE)	8.8 (0.3)	9.4 (0.3)	10.0 (0.7)	7.8 (0.6)
MRI SIJ SPARCC ^c	9.0 (11.4) ^d	6.5 (8.7) ^e	3.9 (6.5) ^f	8.5 (13.4) ^g
Berlin MRI spine ^c	2.1 (3.3) ^h	2.5 (4.0) ⁱ	3.2 (5.0) ^j	1.9 (2.2) ^k
BASFI	5.2 (2.1)	5.4 (2.2)	5.6 (2.5)	5.4 (2.2)
Concomitant medication use, n (%)				
NSAIDs	152 (74.9)	238 (78.8)	26 (76.5)	39 (83.0)
csDMARDs	46 (22.7)	63 (20.9)	5 (14.7)	13 (27.7)
Oral corticosteroids	21 (10.3)	21 (7.0)	1 (2.9)	1 (2.1)

Data are pooled from BE MOBILE 1 and 2. ^aULN value for hs-CRP is 5 mg/L; ^bn=301; ^cOnly patients enrolled in the SIJ and spine MRI substudy and with ≥1 post-baseline record for the respective variable are included; ^dn=100; ^en=152; ^fn=15; ^gn=18; ^hn=99; ⁱn=148; ^jn=14.

Table 2 Change from baseline in pooled efficacy endpoints across BE MOBILE 1 and 2 in TNFi-naïve and TNFi-IR patients at Week 16 and 52 (MI and OC)

CFB (MI), mean (SE), unless otherwise specified	Week 16						Week 52	
	TNFi-naïve			TNFi-IR			TNFi-naïve	TNFi-IR
	PBO n=203	BKZ 160 mg Q4W n=302	Δ	PBO n=34	BKZ 160 mg Q4W n=47	Δ	BKZ 160 mg Q4W, n=495 (432 PY)	BKZ 160 mg Q4W n=47
ASDAS	-0.7 (0.1)	-1.5 (0.1)	0.8	-0.6 (0.1)	-1.6 (0.1)	1.0	-1.8 (0.1)	-1.9 (0.2)
BASDAI	-1.7 (0.1)	-3.0 (0.1)	1.3	-1.6 (0.4)	-2.7 (0.3)	1.1	-3.6 (0.1)	-3.7 (0.3)
MRI SIJ SPARCC [OC] ^a , mean (SD)	-0.9 (7.3) ^b	-5.3 (8.4) ^c	4.4	1.4 (6.0) ^d	-5.6 (13.4) ^e	7.0	-5.9 (9.1) ^f	-6.9 (12.2) ^g
Berlin MRI spine [OC] ^a , mean (SD)	-0.2 (1.5) ^h	-1.4 (3.2) ⁱ	1.2	0.4 (1.3) ^j	-0.5 (1.9) ^k	0.9	-1.7 (3.6) ^l	-1.2 (2.1) ^m
BASFI	-1.1 (0.1)	-2.3 (0.1)	1.2	-0.5 (0.3)	-2.2 (0.3)	1.7	-2.8 (0.1)	-2.9 (0.3)
Nocturnal spinal pain	-1.7 (0.2)	-3.4 (0.2)	1.7	-2.1 (0.5)	-3.3 (0.3)	1.2	-4.1 (0.2)	-3.9 (0.3)
ASQoL	-2.8 (0.3)	-5.1 (0.3)	2.3	-2.4 (0.6)	-4.2 (0.6)	1.8	-5.8 (0.3)	-4.7 (0.6)

Data are pooled from BE MOBILE 1 and 2. Week 52 data shown only for continuous BKZ patients. ^aOnly patients enrolled in the SIJ and spine MRI substudy and with ≥1 post-baseline record for the respective variable are included; ^bn=95; ^cn=144; ^dn=13; ^en=15; ^fn=130; ^gn=94; ^hn=140; ⁱn=12; ^jn=127.

Table 3 Pooled safety overview to Week 52 across BE MOBILE 1 and 2 in TNFi-naïve and TNFi-IR patients

System Organ Class	TNFi-naïve ^a	TNFi-IR ^a
High Level Term		
Preferred Term		
n (%) [EAIR/100 PY]		
Any TEAEs	373 (75.4) [197.8]	61 (77.2) [233.6]
Severe TEAEs	21 (4.2)	3 (3.8)
Study discontinuation due to TEAEs	16 (3.2)	5 (6.3)
Drug-related TEAEs	185 (37.4)	33 (41.8)
Serious TEAEs ^b	24 (4.8)	6 (7.6)
Deaths	0	0
Most frequently reported TEAEs (>5%) by preferred term ^c		
Nasopharyngitis	48 (9.7) [11.9]	12 (15.2) [19.6]
Upper respiratory tract infection	38 (7.7) [9.3]	6 (7.6) [9.3]
Oral candidiasis	33 (6.7) [8.0]	5 (6.3) [7.7]
Headache	28 (5.7) [6.8]	4 (5.1) [6.0]
TEAEs of special monitoring		
Fungal infections ^d	74 (14.9)	9 (11.4)
Colitis (excl. infective)		
Crohn's disease	2 (0.4) [0.5]	0
Ulcerative colitis	2 (0.4) [0.5]	0
Colitis	0	1 (1.3) [1.5]
Uveitis ^e	7 (1.4) [1.6]	3 (3.8) [4.6]

MedDRA (Version 19.0). n is the number of patients reporting at least one TEAE in that category. ^aData reported for both BKZ-randomised patients and patients who had switched from PBO to BKZ at Week 16 and who received at least one dose of BKZ. ^bIncludes TEAEs that were fatal, life threatening, required in-patient hospitalisation or prolongation of existing hospitalisation resulting in persistent or significant disability or incapacity, or any other medically important serious event; ^c>5% in both TNFi-naïve and TNFi-IR patients only; ^dCalculated as the sum of patients reporting at least one TEAE within the high level terms Candida infections, Trinea infections and fungal infections not elsewhere specified; ^eIncludes the preferred terms uveitis, autoimmune uveitis, idiocyclitis and iritis.

